deltatrials
Completed PHASE3 NCT00601900

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Invasive Breast Carcinoma Recurrent Breast Carcinoma Stage III Breast Cancer AJCC v6 Stage IV Breast Cancer AJCC v6 and v7
Interventions Bevacizumab Laboratory Biomarker Analysis Letrozole Questionnaire Administration Tamoxifen Citrate
Updated 54 times since 2017 Last updated: May 9, 2025 Started: Sep 24, 2008 Primary completion: Jun 30, 2014 Completion: May 1, 2025

A PHASE3 clinical study on Invasive Breast Carcinoma and Recurrent Breast Carcinoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 54 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

54 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Apr 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 49 earlier versions

  1. Dec 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Nov 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  7. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  8. Mar 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE3

  9. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE3

  10. Dec 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

  11. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  12. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  13. Jul 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  14. Apr 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE3

  15. Feb 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  16. Dec 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  17. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  18. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  19. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  20. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  21. Jan 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  22. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  23. Oct 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  24. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  25. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  26. Apr 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  27. Feb 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  28. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  29. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  30. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  31. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  32. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  33. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  34. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  35. Mar 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  36. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  37. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  38. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  39. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  40. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  41. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  42. Apr 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  43. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  44. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  45. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  46. Jun 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  47. Nov 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  48. Feb 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE3

  49. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States, Abington, United States, Alexandria, United States, Allentown, United States, Alton, United States, Ames, United States, Anderson, United States, Ann Arbor, United States, Antigo, United States, Antioch, United States and 330 more location s